Leanne M Fox1. 1. Division of Infectious Diseases, Children's Hospital, Boston, Massachusetts 02115, USA. leanne.fox@childrens.harvard.edu
Abstract
PURPOSE OF REVIEW: Ivermectin was first discovered and used in veterinary medicine over 20 years ago. This review highlights some of the recent published research from 2005 through June 2006 on the use of ivermectin in both helminth and arthropod infection. RECENT FINDINGS: In recent years, several published studies have detailed the expanding role for ivermectin in multiple endo and ectoparasitic infections, including scabies, pediculosis, soil transmitted helminths, gnathostomiasis and myiasis. In addition, there is increasing experience with parenteral ivermectin for the treatment of disseminated strongyloidiasis. The success of ivermectin in reducing Onchocerca volvulus and Wuchereria bancrofti transmission through universal treatment in disease control programs continues to be well documented, but recent epidemiologic data describe suboptimal response to ivermectin by O. volvulus in a minority of individuals, the molecular markers for which are currently under investigation. SUMMARY: Over 20 years of research and clinical use have advanced ivermectin from its beginnings as a veterinary anthelmintic to its significant role in several successful disease control programs. Nevertheless, further research is needed to understand the basis for suboptimal response and to better define optimal drug regimens for varying diseases.
PURPOSE OF REVIEW: Ivermectin was first discovered and used in veterinary medicine over 20 years ago. This review highlights some of the recent published research from 2005 through June 2006 on the use of ivermectin in both helminth and arthropod infection. RECENT FINDINGS: In recent years, several published studies have detailed the expanding role for ivermectin in multiple endo and ectoparasitic infections, including scabies, pediculosis, soil transmitted helminths, gnathostomiasis and myiasis. In addition, there is increasing experience with parenteral ivermectin for the treatment of disseminated strongyloidiasis. The success of ivermectin in reducing Onchocerca volvulus and Wuchereria bancrofti transmission through universal treatment in disease control programs continues to be well documented, but recent epidemiologic data describe suboptimal response to ivermectin by O. volvulus in a minority of individuals, the molecular markers for which are currently under investigation. SUMMARY: Over 20 years of research and clinical use have advanced ivermectin from its beginnings as a veterinary anthelmintic to its significant role in several successful disease control programs. Nevertheless, further research is needed to understand the basis for suboptimal response and to better define optimal drug regimens for varying diseases.
Authors: Julie Gutman; Emmanuel Emukah; Njideka Okpala; Chinyere Okoro; Andrew Obasi; Emmanuel S Miri; Frank O Richards Journal: Am J Trop Med Hyg Date: 2010-09 Impact factor: 2.345
Authors: Abebe Genetu Bayih; Anjan Debnath; Edward Mitre; Christopher D Huston; Benoît Laleu; Didier Leroy; Benjamin Blasco; Brice Campo; Timothy N C Wells; Paul A Willis; Peter Sjö; Wesley C Van Voorhis; Dylan R Pillai Journal: Clin Microbiol Rev Date: 2017-07 Impact factor: 26.132
Authors: David S Goodsell; Christine Zardecki; Luigi Di Costanzo; Jose M Duarte; Brian P Hudson; Irina Persikova; Joan Segura; Chenghua Shao; Maria Voigt; John D Westbrook; Jasmine Y Young; Stephen K Burley Journal: Protein Sci Date: 2019-11-29 Impact factor: 6.725
Authors: Zhu Wang; X Edward Zhou; Daniel L Motola; Xin Gao; Kelly Suino-Powell; Aoife Conneely; Craig Ogata; Kamalesh K Sharma; Richard J Auchus; James B Lok; John M Hawdon; Steven A Kliewer; H Eric Xu; David J Mangelsdorf Journal: Proc Natl Acad Sci U S A Date: 2009-06-02 Impact factor: 11.205
Authors: Mohammad Ali; Mohammad Afzal; Meenakshi Verma; Shailja Misra Bhattacharya; F J Ahmad; Mohammad Samim; M Z Abidin; A K Dinda Journal: Parasitol Res Date: 2013-12-24 Impact factor: 2.289